Advisors Capital Management LLC Purchases 20,147 Shares of AbbVie Inc. $ABBV

Key Points

• Advisors Capital Management LLC increased its Q4 position in AbbVie by 3.3%, buying 20,147 shares to hold 634,242 shares worth $144,918,000, making AbbVie ~1.7% of its portfolio and its 6th largest holding.
• AbbVie beat Q4 estimates (EPS $2.71 vs $2.65) with revenue up 10%, set FY2026 guidance of $14.370–$14.570 EPS and Q1 guidance of $2.970–$3.010, and announced a quarterly dividend of $1.73 (annual $6.92, ~3.5% yield).
• The U.S. FDA issued a Complete Response Letter for AbbVie’s trenibotulinumtoxinE due to manufacturing/process issues, delaying potential commercialization and creating near-term regulatory uncertainty.

Advisors Capital Management LLC increased its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 3.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 634,242 shares of the company's stock after purchasing an additional 20,147 shares during the quarter. AbbVie makes up approximately 1.7% of Advisors Capital Management LLC's investment portfolio, making the stock its 6th largest position. Advisors Capital Management LLC's holdings in AbbVie were worth $144,918,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Diversified Trust Co raised its stake in shares of AbbVie by 23.6% in the third quarter. Diversified Trust Co now owns 57,076 shares of the company's stock worth $13,215,000 after acquiring an additional 10,891 shares during the last quarter. Permanent Capital Management LP bought a new stake in shares of AbbVie during the third quarter valued at approximately $720,000. Railway Pension Investments Ltd grew its stake in shares of AbbVie by 33.0% during the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company's stock valued at $197,723,000 after purchasing an additional 211,800 shares during the last quarter. Public Sector Pension Investment Board increased its holdings in shares of AbbVie by 17.0% in the third quarter. Public Sector Pension Investment Board now owns 1,044,690 shares of the company's stock valued at $241,888,000 after purchasing an additional 151,644 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of AbbVie by 0.3% in the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company's stock valued at $41,155,601,000 after purchasing an additional 448,554 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.06% of the company's stock.

AbbVie Stock Performance

Shares of ABBV stock opened at $198.71 on Friday. The firm's 50 day moving average price is $216.68 and its two-hundred day moving average price is $222.33. AbbVie Inc. has a 52-week low of $176.57 and a 52-week high of $244.81. The stock has a market cap of $351.35 billion, a PE ratio of 84.20, a PEG ratio of 0.72 and a beta of 0.38.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts' expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business's revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, sell-side analysts predict that AbbVie Inc. will post 14.21 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.5%. The ex-dividend date is Wednesday, April 15th. AbbVie's dividend payout ratio is currently 293.22%.

Analysts Set New Price Targets

Several research firms have issued reports on ABBV. Weiss Ratings reaffirmed a "hold (c)" rating on shares of AbbVie in a report on Wednesday, January 21st. The Goldman Sachs Group reissued a "neutral" rating and issued a $223.00 target price on shares of AbbVie in a research note on Wednesday, January 28th. BMO Capital Markets restated an "outperform" rating on shares of AbbVie in a research report on Monday, March 9th. Royal Bank Of Canada assumed coverage on AbbVie in a research note on Tuesday, February 24th. They set an "outperform" rating and a $260.00 price target on the stock. Finally, UBS Group decreased their price target on AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a report on Thursday, February 5th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $253.19.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a major strategic investment: a $1.4 billion, AI-enabled manufacturing campus in Durham, NC that will create hundreds of permanent jobs and supports capacity for immunology, neuroscience and oncology medicines. This strengthens manufacturing footprint and long-term growth/production capacity. Article Title
• Positive Sentiment: Canaccord initiated coverage with a Buy and $262 price target (recent coverage highlighted AbbVie as a buy on pullback), providing bullish analyst support and upside from current levels. Analyst upgrades can buoy sentiment and attract inflows. Article Title
• Positive Sentiment: AbbVie struck an exclusive licensing deal with Haisco for development of pain medicines, expanding its pipeline and potential addressable market for pain therapeutics. Partnership deals can add optionality to future revenue. Article Title
• Neutral Sentiment: Wall Street previews and model-level estimates for Q1 (sales and key metric breakdowns) are circulating ahead of AbbVie’s April 29 earnings; these projections set expectations traders will use for the report. Meeting or beating estimates could stabilize the stock. Article Title
• Neutral Sentiment: Analysts and media continue to discuss AbbVie as a dividend-growth candidate and a long-term defensive healthcare holding; this maintains baseline investor interest but is unlikely to move shares sharply near-term. Article Title
• Negative Sentiment: The U.S. FDA issued a Complete Response Letter (CRL) for AbbVie’s trenibotulinumtoxinE (TrenibotE) — citing manufacturing/process issues rather than new clinical trials. AbbVie said it will respond and believes it can address comments, but the CRL delays potential commercialization and near-term revenue expectations for the neurotoxin program. Article Title
• Negative Sentiment: Multiple outlets report the CRL is tied to manufacturing concerns; while AbbVie noted no additional clinical studies were requested, regulatory manufacturing issues create uncertainty on timing and cost to obtain approval — a near-term headwind for sentiment. Article Title

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.